Cimetidine HCl Oral Solution Recalled Due to Manufacturing Compliance Deviations
Akorn, Inc. is recalling all lots of Cimetidine HCl Oral Solution 300mg/5mL nationwide due to CGMP deviations. The firm ceased operations and could not complete required stability studies.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall due to CGMP deviations and incomplete stability studies. No illnesses or injuries have been reported. The hazard is precautionary and theoretical rather than an identified contamination or defect.
Plain-English summary
Akorn, Inc. is recalling Cimetidine HCl Oral Solution 300mg/5mL in 237 mL bottles (Rx only) distributed nationwide in the USA and Puerto Rico. All lot numbers are included in this recall.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The firm went out of business and could no longer continue the required stability studies necessary to ensure the product's safety and efficacy.
Patients currently taking this medication should consult their healthcare provider immediately to discuss alternatives or next steps. Do not stop taking the medication without speaking to a doctor. Pharmacies and healthcare facilities should identify and quarantine all affected product.
The recalled product
- Product
- Cimetidine HCl Oral Solution 300mg/5mL, 237 mL bottles, Rx Only, Distributed by: Akorn Operating Company, LLC., Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Oral Solution
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- ModerateCiprofloxacin ophthalmic solution recalled for manufacturing practice deviations
FDA (Drugs) · 2023-01-25
- LowAkorn Recalls Gabapentin Oral Solution Due to Unapproved Manufacturer
FDA (Drugs) · 2018-01-17
- ModerateOlopatadine HCl ophthalmic solution recalled for manufacturing deviations
FDA (Drugs) · 2023-01-25
- ModerateCimetidine Hydrochloride Oral Solution Recalled for CGMP Violation
FDA (Drugs) · 2021-08-18
- LowAkorn Recalls Azelastine HCl Ophthalmic Solution Due to Impurities
FDA (Drugs) · 2018-09-05
- ModeratePrescription eye drop recall due to manufacturing compliance issues
FDA (Drugs) · 2023-01-25